Health · 4 views
Moderna stock surges as melanoma vaccine trial shows "landmark moment"
Drugmaker Moderna's stock more than doubled on Wednesday morning after the company announced a successful experimental mRNA vaccine to tr…
Story Brief
Drugmaker Moderna's stock more than doubled on Wednesday morning after the company announced a successful experimental mRNA vaccine to treat melanoma , the deadly skin cancer from which more than 8,500 people in the U.S. are expected to die this year. Moderna and Merck, its drug development partner, said the novel treatment prevented melanoma from returning or spreading in a study of high-risk melanoma patients.
Read full article on CBS NewsAI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Specialized imaging reveals hormone-driven brain changesContinue reading
- Cell-preservation technique could make CAR-T cell therapy more accessibleContinue reading
- Real-world study of Oregon's nonmedical psilocybin program shows promiseContinue reading
- STAT+: American Cancer Society cancels alcohol industry fundraiserContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow